CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $303,021 | +65.0% | 10,189 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $183,606 | +45.3% | 10,189 | +29.5% | 0.00% | 0.0% |
Q1 2023 | $126,360 | -4.6% | 7,868 | +8.7% | 0.00% | 0.0% |
Q4 2022 | $132,510 | -8.6% | 7,241 | -2.2% | 0.00% | 0.0% |
Q3 2022 | $145,000 | +5.1% | 7,405 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $138,000 | -15.9% | 7,405 | -1.2% | 0.00% | 0.0% |
Q1 2022 | $164,000 | -9.4% | 7,493 | +17.4% | 0.00% | 0.0% |
Q4 2021 | $181,000 | – | 6,383 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |